Anti-GITR antibodies and methods of use thereof

US11401335B2 · kind B2 · utility

Assignees

• Agenus Inc. · US
• Memorial Sloan Kettering Cancer Center · US
• LUDWIG INSTITUTE FOR CANCER RESEARCH LTD · GB

Inventors

• Ana M. GONZALEZ · Cambridge, US
• Nicholas Stuart Wilson · Melbourne, AU
• Dennis John Underwood · Brookline, US
• Volker Seibert · Lörrach, DE
• Olivier Leger · Bonneville, FR
• Marc van Dijk · Bosch en Duin, NL
• Roberta Zappasodi · New York, US
• Taha Merghoub · New York, US
• Jedd D. Wolchok · New York, US
• David Schaer · Mamaroneck, US
• Gerd Ritter · New York, US
• Takemasa TSUJI · Williamsville, US

Key dates

• Filing date: Jan 15, 2020
• Grant date: Aug 2, 2022
• Expiry date: Jan 15, 2040

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.